Lamotrigine-13C3

• CAT Number: R003811
• CAS Number: 1188265-38-4
• Molecular Formula: C9H7Cl2N5
• Molecular Weight: 259.067
• Purity: ≥95%
• Synonyms: 6-(2,3-Dichlorophenyl)-1,2,4-triazine-3,5-diamine-13C3; 3,5-Diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine-13C3; BW 430C-13C3; LTG-13C3; Lamictal-13C3; Lamictal XR-13C3; Lamotrigin-13C3
• Storage: 3 years -20C powder
• IUPAC Name: 6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine
• InChI: InChI=1S/C9H7Cl2N5/c10-5-3-1-2-4(6(5)11)7-8(12)14-9(13)16-15-7/h1-3H,(H4,12,13,14,16)/i7+1,8+1,9+1
• InChIKey: PYZRQGJRPPTADH-ULEDQSHZSA-N
• SMILES: C1=CC(=C(C(=C1)Cl)Cl)C2=C(N=C(N=N2)N)N

Lamotrigine-13C3 (CAS 1188265-38-4)  is an isotopically labeled form of Lamotrigine. Lamotrigine is an inhibitor of voltage gated sodium channels of presynaptic neurons. Studies indicate that Lamotrigine blocked sustained repetitive firing of neurons in a dose dependent manner in cultured mouse spinal cords. Lamotrigine is effective at suppressing the release of glutamate and aspartate, but have no effect on acetylcholine and GABA release. Lamotrigine is inactivated by liver microsomes, via hepatic glucuronidation. It is believed that Lamotrigine modulates the fast voltage-dependent sodium currents in a manner similar to phenytoin and carbamazepine. Furthermore, Lamotrigine displays a small frequency dependent inhibition of depolarized potentials that result from sodium currents. Lamotrigine-13C3 can be beneficial in research due to its isotopic label, which makes identification of the molecule easier in situ.

 

Reference

1.Cohen, A. F., et al. "Lamotrigine (BW430C), a potential anticonvulsant. Effects on the central nervous system in comparison with phenytoin and diazepam." British journal of clinical pharmacology 20.6 (1985): 619-629.
2.Riddall, Dieter R., Michael J. Leach, and John Garthwaite. "A novel drug binding site on voltage-gated sodium channels in rat brain." Molecular pharmacology 69.1 (2006): 278-287.
3.Papazisis, Georgios, et al. "Neuroprotection by lamotrigine in a rat model of neonatal hypoxic-ischaemic encephalopathy." International Journal of Neuropsychopharmacology 11.3 (2008): 321-329.
4.Lagrue, Emmanuelle, et al. "Lamotrigine is neuroprotective in the energy deficiency model of MPTP intoxicated mice." Pediatric research 62.1 (2007): 14-19.
5.Miller, Alistair A., et al. "Pharmacological studies on lamotrigine, a novel potential antiepileptic drug: I. Anticonvulsant profile in mice and rats." Epilepsia 27.5 (1986): 483-489.
6.Leach, Michael J., Caroline M. Marden, and Alistair A. Miller. "Pharmacological studies on lamotrigine, a novel potential antiepileptic drug: II. Neurochemical studies on the mechanism of action." Epilepsia 27.5 (1986): 490-497.
7.Binnie, C. D., et al. "Acute effects of lamotrigine (BW430C) in persons with epilepsy." Epilepsia 27.3 (1986): 248-254.